Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
The DOI matches its Crossref record; 123 of the 130 references it cites were found in a registry or an index.
Abstract
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a)…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence favors the need to assess apo Becontaining lipoproteins to account for remnant lipoproteins and small dense lipoproteins responsible for residual ASCVD risk not seen with a standard lipid panel of total cholesterol, LDL-C, and HDL-C.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [314]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · cited 14×
“adults, 112 mg/dL (3), is higher than the recommended LDL-C goal of <100 mg/dL for those with moderate ASCVD risk and well above the goals for people at high risk of ASCVD (1).”
InfluentialCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 6×
“Outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in which achieved LDL-C levels were substantially lower than those in statin trials further reinforced the notion that “lower is better” (24,25).”
InfluentialThe Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Research works printed but not linked: 4
- Sever, 2003, J Am Coll Cardiol., 361, 1149
- Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Cardiovasc Diabetol., 366, 1849
- 2000, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease, N Engl J Med., 102, 21
- Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
Cited by
Items 201–246 of 246
Santos, L. L. M. T., Maia, F. P. A., Neto, L. S. E. S., Soares, N. L. M., Vasconcelos, L. M., & Neto, V. L. M. (2022) · Amplla Editora eBooks · doi:10.51859/amplla.ecc136.1122-9
Portela, A. L., Altino, M. P., Muniz, F. M., Vasconcelos, A. D. C. B. E., & de Olivindo, R. G. (2022) · Amplla Editora eBooks · doi:10.51859/amplla.ecc136.1122-16
Complicações agudas de DM1 e DM2
Muniz, F. M., dos Santos, E. R., de Carvalho, A. B. S., Filho, R. E. P. C., Santos, L. L. M. T., & Muniz, A. A. (2022) · Amplla Editora eBooks · doi:10.51859/amplla.ecc136.1122-3
“Incorporating a Gym Facility in a Lifestyle Medicine Practice for Patients with Diabetes Mellitus”
Nadolsky, K. Z., Baraki, A., & Nadolsky, S. (2022) · American Journal of Lifestyle Medicine · doi:10.1177/15598276221089898 · Cited by 2
Pérez, A., de Victoria, E. O. M., Blanco, F. A., Caixàs, A., Mazo, E. S., Fernández-Catalina, P., Martínez‐Hervás, S., Medina, J. A., Suárez-Gutiérrez, L., Planelles, J. R. U., et al. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.07.002 · Cited by 1
Santos, T. L., Lima, C. S. D. A., Roman, R. F., Cunha, L. T. B. L., Gomes, M. E. D. A., Freitas, B. G. C. D., Andrade, A. C. B. A., Foloni, B. V., Neto, W. L. D. S., Figueredo, S. R. R., et al. (2022) · Research Society and Development · doi:10.33448/rsd-v11i14.36042
The role of testicular microcirculatory disorders in spermatogenic dysfunction in obese menPreprint
Fu, W., Cui, J., & Tang, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2343004/v1
Ganda, O. P., Busch, R. S., Nelson, J. R., & Philip, S. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_25
Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Self-citationPonir, C., Annabathula, R. V., Caldarera, T., Penmetsa, M., Seals, A. L., Saha, A., Moore, J. B., Bosworth, H. B., Ip, E. H., Shapiro, M. D., et al. (2023) · Southern Medical Journal · doi:10.14423/smj.0000000000001617
“Furthermore, team-based multidisciplinary clinical practice is becoming more common and perhaps more effective in the management of various diseases than care provided by physicians only, 5 – 7 , 9 –”
BackgroundJang, M.-G., Son, Y.-E., Choi, H. D., Kim, J., Kim, T., & Shin, K. (2023) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2023.33.4.270
Kheir, O. O., Dossary, S., Dhalaan, M., AlHajri, S., Aljeshi, A., Dawoud, R. W., & Ghamdi, M. (2024) · Qeios · doi:10.32388/t52nt9
“The key to preventing dyslipidaemia is to promote moderate exercise and a healthy diet [33] .”
BackgroundKheir, O. O., Dossary, S., Dhalaan, M., AlHajri, S., Aljeshi, A., Dawoud, R. W., & Ghamdi, M. (2024) · Qeios · doi:10.32388/t52nt9.3
Kheir, O. O., Dossary, S., Dhalaan, M., AlHajri, S., Aljeshi, A., Dawoud, R. W., & Ghamdi, M. (2024) · Qeios · doi:10.32388/t52nt9.4
Gomes, S. P., de Oliveira, V. P. S., de Jesus, F. F., Abdala, F. C. M., Schimming, B. C., Dias, F. G. G., Kfoury, J. R., & Sasahara, T. H. D. C. (2024) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv16n6-110
Dislipidemia en personas de edad muy avanzada
Friocourt, P. (2024) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(24)49306-9
Novel approaches to treat primary hyperlipidemia
Vachhani, J. M., & Tirgar, P. (2024) · American Journal of Biopharmacy and Pharmaceutical Sciences · doi:10.25259/ajbps_7_2024
Dislipidemie del grande anziano
Friocourt, P. (2024) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(24)49439-4
Jasaputra, D. K., Rahardjo, T. M., Gunadi, J. W., Stefani, S., & Sutrisno, I. I. (2024) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2024.587.593
Ilias, N. F., Omar, M., Kassim, S. S., & Ismail, H. (2024) · doi:10.56984/8zg020cm4cl
Николаевна, К. Е., & Baiko, S. (2025) · Nephrology and Dialysis · doi:10.28996/2618-9801-2025-1-38-58
Fstkchian, A. K., Lowe, R. N., & Saseen, J. J. (2025) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2025.102395 · Cited by 1
Eidensohn, Y., & O’Rourke, P. (2025) · Cureus · doi:10.7759/cureus.83859 · Cited by 1
“…testing Lp(a) in all patients with primary severe hypercholesterolemia (low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL) or premature ASCVD, which the American Association of Clinical Endocrinologists/American College of Endocrinology extends to all patients with established ASCVD [7,13].”
Nevill, A. M., Duncan, M. J., & SANDERCOCK, G. R. H. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01835-0 · Cited by 1
“…regardless of adiposity [60] and, of note, guidelines for exercise prescription in patients with dyslipidaemia are based dually on the direct association of aerobic exercise on lipid pro fi le (reducing TC, LDL and increasing HDL) and the indirect bene fi ts from promoting weight loss [32, 35, 61].”
Demystifying the nuances of the lipid patient: a guide for primary care providers
Myerson, M. L., Gillett, K., O’Hara, J., Potter, R., & SKOLNIK, N. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101070
Calcium score: what do the most reliable guidelines recommend? An analysis using the G-TRUST tool
Vincent, Y.-M., Gocko, X., François, C., Supper, I., Cauchon, M., & Boussageon, R. (2025) · Family Practice · doi:10.1093/fampra/cmaf079
Hong, S., Kim, W. J., Kim, S., Park, J. H., Kang, E. S., Moon, M. K., Kim, J. T., Mok, J., Lee, K., Park, C., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70258
Yin, M., Cui, F., Xu, X., Yang, Y., Chen, S., Sun, Y., Zhen, Y., Zhai, H., Wu, S., & Fang, H. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.009
Chen, X., Hou, C., Yao, L., Li, J., 桂明泰, Wang, M., Zhou, X., Lu, B., & Fu, D. (2024) · Figshare · doi:10.6084/m9.figshare.26616211
Additional file 1 of Serum LDL-C/HDL-C ratio and the risk of carotid plaques: a longitudinal study
Wu, Z., Li, X., Wen, Q., Tao, B., Qiu, B., Zhang, Q., & Wang, J. (2022) · Figshare · doi:10.6084/m9.figshare.21628738
Lin, L., Kiryakos, J., Ammous, F., Ratliff, S. M., Ware, E. B., Faul, J. D., Kardia, S. L. R., Zhao, W., Birditt, K. S., & Smith, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.25910051
Shi, R., Gao, Y., Shen, L.-L., Shi, K., Wang, J., Jiang, L., Li, Y., & Yang, Z.-G. (2022) · Figshare · doi:10.6084/m9.figshare.20208430
Belay, K. E., Abebe, D. G., Aynalem, M. W., & Taye, M. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf301
“The milder form, known as heterozygous FH (HeFH), is inherited from 1 parent, while the more severe form, homozygous FH, is inherited from both parents [2].”
Jeanwiwattanavong, S., Sitaruno, S., Mahattanadul, S., & Sae-lim, O. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70158
“The LDL cholesterol level target was determined by a 10-year risk of atherosclerotic cardiovascular disease (10-year risk > 20% = target BP < 100 mg/dL; 10-year risk 10%–20% = BP < 130 mg/dL; 10-year risk < 10% = BP < 160 mg/ dL) [3].”
SEA 2026 Standards for Global Control of Vascular Risk
Mostaza, J. M., Pintó, X., Armario, P., Guijarro, C., Masana, L., Real, J. T., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500889 · Cited by 3
Lipoprotein(a) Augments Coronary Risk Estimation in Type 2 Diabetes: A Cross-sectional Study
Sharma, S., Chandak, R. K., Sharma, K. K., Guptha, S., & Gupta, R. K. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1331
Abordagem da dislipidemia na síndrome dos ovários policísticos
Costa, L. O. B. F., & Soares, G. M. (2021) · Femina · doi:10.61622/0100-7254499202102 · Cited by 7
Zhao, Y., Li, Z. L., Yu, T., Yang, Y., & Du, T. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005841
“11 25–27 Therefore, four mutually exclusive concordance/discordance groups were defined based on the cut-off points of LDL-C and RC: low/low (less than the cut-off points of both LDL-C and RC), low/high (less than the cut-off points of LDL-C and greater than or equal to the cut-off points of RC),…”
Aydagnuhm, G. B., & Melaku, E. E. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100613
Zhu, L., Wang, M. D., Song, X., Yan, T., Zheng, G., Tai, Y., Liu, T., Luo, S., Kolberg, B., & Li, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1883414
“It typically features elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG), along with reduced high-density lipoprotein cholesterol (HDL-C) (4).”
Dyslipidémies de la personne très âgée
Friocourt, P. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)49515-2
Akers, K., Nguyen, K., Frederickson, A. M., Bash, L. D., Ke, X., & Goodman, S. G. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200710
“However, some guidance documents also recommend the addition of a bile acid sequestrant or bempedoic acid [2,32, 73].”
Sydora, B. C., Ghosh, M., Chambers, S., Haase, A., Davenport, M. H., Beaulieu, C., Thompson, R. B., Windram, J., Becher, H., Raggi, P., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-124025
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
“In patients with new-onset, worsening, or refractory HTG, a systematic assessment of glucose metabolism, thyroid function, kidney function, liver function, urine protein, and relevant endocrine conditions is an important part of etiologic evaluation [ 83 ].”
Talkhan, A., Elkasaby, M. H., Elezz, A. M. A., Borham, N. E., Abbas, A. N., Abbas, A. W., Hammad, N., khalefa, K. A., & Shehata, M. (2026) · Endocrine · doi:10.1007/s12020-026-04805-2 · Cited by 1
Metadata
- Authors
- Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., Garber, A. J., Grunberger, G., Krauss, R. M., Mechanick, J. I., Rosenblit, P. D., Smith, D. A., & Wyne, K. L.
- Affiliations
- University of Miami (US)
- University of California San Diego (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of California, Los Angeles (US)
- University of Chicago (US)
- Oregon Health & Science University (US)
- Tulane University (US)
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California, San Francisco (US)
- University of California, Irvine (US)
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- Handelsman, Yehuda
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 26
- Issue
- 10
- Pages
- 1196-1224
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3095590613
- Cited by
- 248
- References
- 130
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 58 · 2023: 50 · 2022: 57 · 2021: 26 · 2020: 1
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- dyslipidemia management, atherosclerotic cardiovascular disease prevention, LDL cholesterol targets, high-intensity statin therapy, PCSK9 inhibitors, ezetimibe, colesevelam, bempedoic acid, triglyceride-lowering therapy, fibrates, omega-3 fatty acids, nicotinic acid, icosapent ethyl, lipoprotein(a), statin intolerance, lifestyle therapy, cardiovascular risk stratification
- MeSH terms
- Endocrinologists, Algorithms, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Risk Factors, United States, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Consensus, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.